OTC - ACTIVE INGREDIENT SECTION
Active Ingredient Purpose
Undecylenic Acid 3%........................Anti-fungal
Active Ingredient Purpose
Undecylenic Acid 3%........................Anti-fungal
Do not use on children under 2 years of age unless directed by a doctor.
KEEP THIS AND ALL MEDICATION OUT OF REACH OF CHILDREN.In case of accidental ingestion, contact a physician, emergency medical care facility or poison control center immediately for advice.
When using this product avoid contact with eyes.
Stop use and ask a doctor if irritation occurs.
Clean nails and dry thoroughly.
Remove any nail polish with nail
polish remover. Allow to dry
thoroughly. Roll your bottle of Fioré
Rx Antifungal Nail Lacquer in between
your hands to mix the lacquer
thoroughly. Do not shake the bottle,
as this can introduce air bubbles that
will affect the quality of the lacquer.
Using only the brush provided in the
Fioré Rx bottle, apply a strip of
lacquer down the middle of your nail
from cuticle to tip before following it
with lacquer on either side. Allow
lacquer to dry for at least 2 minutes.
For best results, apply a second coat
and allow to dry for 30 minutes.
Butyl acetate, ethyl acetate, nitrocellulose, adipic acid/neopentyl glycol/trimellitic anhydride copolymer, acetyl tributyl citrate, isopropyl alcohol, propolis wax
CI 60725, Benzophenone-3,
Bensophenone-1, Acrylates Copolymer,
Stearalkonium Bentonite, CI 15880, CI
15850, Silica, N-Butyl Alcohol, CI
15850:1, CI 77891,
Trimethylpentanediyl Dibenzoate,
Styrene Acrylates Copolymer,Mica, Tin
Oxide, CI 77510, CI 19140, CI 77491
| RxCUI | RxNorm string | TTY | SPL version |
|---|---|---|---|
| 1437982 | Fiore Rx Antifungal 3 % Nail Polish | PSN | 7 |
| 1437977 | Undecylenic Acid 3 % Topical Solution | PSN | 7 |
| 1437982 | undecylenic acid 30 MG/ML Topical Solution [Fiore] | SBD | 7 |
| 1437977 | undecylenic acid 30 MG/ML Topical Solution | SCD | 7 |
| 1437982 | Fiore 30 MG/ML Topical Solution | SY | 7 |
| 1437982 | Fiore Rx 3 % Nail Polish | SY | 7 |
| 1437977 | Undecylenic Acid 3 % Topical Solution | SY | 7 |
| NDC | Effective | Action | Document | Indexing SPL | Related label |
|---|---|---|---|---|---|
| 52261-0201-0 | 2020-01-31 | C162847 | 48780-1 | 9d75b9d0-db7c-f424-e053-dadaa90a57ce | Drug Facts |
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 52261-0201-0 | Fiore Rx Antifungal Nail Lacquer Red Velvet Cake | 15 mL in 1 BOTTLE, WITH APPLICATOR | FILM | 15 | 7 |
| NDC | Dashboard title | SPL version | Validation | Dashboard ZIP |
|---|---|---|---|---|
| 52261-0201 | FIORE RX ANTIFUNGAL NAIL LACQUER RED VELVET CAKE (UNDECYLENIC ACID) FILM [COSCO INTERNATIONAL, INC.] | 7 | Legacy NDC, 1 package rows | 20130919_573091aa-78a0-41e0-a6f2-ac0076e9cc8f.zip |
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| Undecylenic Acid | ACTIVE INGREDIENT | K3D86KJ24N | 7 | |
| Undecylenic Acid | ACTIVE MOIETY | K3D86KJ24N | 7 | |
| Acetyltributyl Citrate | INACTIVE INGREDIENT | 0ZBX0N59RZ | 7 | |
| Bentoquatam | INACTIVE INGREDIENT | 7F465U79Q1 | 7 | |
| Benzoresorcinol | INACTIVE INGREDIENT | LJ54R4Z029 | 7 | |
| Butyl Acetate | INACTIVE INGREDIENT | 464P5N1905 | 7 | |
| Butyl Alcohol | INACTIVE INGREDIENT | 8PJ61P6TS3 | 7 | |
| D&C Red No. 34 | INACTIVE INGREDIENT | BAN556989E | 7 | |
| D&C Red No. 6 | INACTIVE INGREDIENT | 481744AI4O | 7 | |
| D&C Red No. 7 | INACTIVE INGREDIENT | ECW0LZ41X8 | 7 | |
| DIMETHYLAMINOETHYL METHACRYLATE - BUTYL METHACRYLATE - METHYL METHACRYLATE COPOLYMER | INACTIVE INGREDIENT | 905HNO1SIH | 7 | |
| Ethyl Acetate | INACTIVE INGREDIENT | 76845O8NMZ | 7 | |
| Isopropyl Alcohol | INACTIVE INGREDIENT | ND2M416302 | 7 | |
| POLYESTER-10 | INACTIVE INGREDIENT | 212N9O2MMZ | 7 | |
| PROPOLIS WAX | INACTIVE INGREDIENT | 6Y8XYV2NOF | 7 | |
| Pyroxylin | INACTIVE INGREDIENT | KYR8BR2X6O | 7 | |
| Silicon Dioxide | INACTIVE INGREDIENT | ETJ7Z6XBU4 | 7 | |
| Trimethylpentanediyl Dibenzoate | INACTIVE INGREDIENT | Y8PB83G67A | 7 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 52261-0201 | 52261-0201-0 |
Every source-derived ingredient row is available through these pages.
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| Silicon Dioxide | SILICON DIOXIDE | ETJ7Z6XBU4 | CAPSULE, COATED / ORAL | 3 mg | ||
| Silicon Dioxide | SILICON DIOXIDE | ETJ7Z6XBU4 | TABLET, COATED / ORAL | 176 mg | ||
| Silicon Dioxide | SILICON DIOXIDE | ETJ7Z6XBU4 | LOZENGE / ORAL | 120 mg | ||
| Acetyltributyl Citrate | ACETYLTRIBUTYL CITRATE | 0ZBX0N59RZ | TABLET / ORAL | 150 mg | ||
| Butyl Alcohol | BUTYL ALCOHOL | 8PJ61P6TS3 | CAPSULE, EXTENDED RELEASE / ORAL | 0.01 mg | ||
| Silicon Dioxide | SILICON DIOXIDE | ETJ7Z6XBU4 | GEL / DENTAL | 19 %w/w | ||
| Silicon Dioxide | SILICON DIOXIDE | ETJ7Z6XBU4 | GRANULE / ORAL | 5000 mg | ||
| Isopropyl Alcohol | ISOPROPYL ALCOHOL | ND2M416302 | SOLUTION / TOPICAL | 40 %w/v | ||
| Isopropyl Alcohol | ISOPROPYL ALCOHOL | ND2M416302 | SWAB / TOPICAL | 43.9 %w/w | ||
| Butyl Alcohol | BUTYL ALCOHOL | 8PJ61P6TS3 | TABLET, COATED / ORAL | NA | ||
| Acetyltributyl Citrate | ACETYLTRIBUTYL CITRATE | 0ZBX0N59RZ | CAPSULE / ORAL | 7 mg | ||
| Butyl Alcohol | BUTYL ALCOHOL | 8PJ61P6TS3 | CAPSULE, DELAYED RELEASE / ORAL | NA | ||
| Isopropyl Alcohol | ISOPROPYL ALCOHOL | ND2M416302 | LOTION, AUGMENTED / TOPICAL | 2070 mg | ||
| Butyl Alcohol | BUTYL ALCOHOL | 8PJ61P6TS3 | TABLET / ORAL | 0.01 mg | ||
| Butyl Alcohol | BUTYL ALCOHOL | 8PJ61P6TS3 | TABLET, EXTENDED RELEASE / ORAL | NA | ||
| Acetyltributyl Citrate | ACETYLTRIBUTYL CITRATE | 0ZBX0N59RZ | TABLET, EXTENDED RELEASE / ORAL | 309 mg | ||
| DIMETHYLAMINOETHYL METHACRYLATE - BUTYL METHACRYLATE - METHYL METHACRYLATE COPOLYMER | DIMETHYLAMINOETHYL METHACRYLATE - BUTYL METHACRYLATE - METHYL METHACRYLATE COPOLYMER | 905HNO1SIH | SUSPENSION / ORAL | 255 mg | ||
| Silicon Dioxide | SILICON DIOXIDE | ETJ7Z6XBU4 | POWDER, FOR SUSPENSION / ORAL | 2553 mg | ||
| DIMETHYLAMINOETHYL METHACRYLATE - BUTYL METHACRYLATE - METHYL METHACRYLATE COPOLYMER | DIMETHYLAMINOETHYL METHACRYLATE - BUTYL METHACRYLATE - METHYL METHACRYLATE COPOLYMER | 905HNO1SIH | FILM, EXTENDED RELEASE / TRANSDERMAL | NA | ||
| D&C Red No. 7 | D&C RED NO. 7 | ECW0LZ41X8 | TABLET / ORAL | 0.5 mg | ||
| DIMETHYLAMINOETHYL METHACRYLATE - BUTYL METHACRYLATE - METHYL METHACRYLATE COPOLYMER | DIMETHYLAMINOETHYL METHACRYLATE - BUTYL METHACRYLATE - METHYL METHACRYLATE COPOLYMER | 905HNO1SIH | TABLET, EXTENDED RELEASE / ORAL | 60 mg | ||
| Silicon Dioxide | SILICON DIOXIDE | ETJ7Z6XBU4 | GRANULE, DELAYED RELEASE / ORAL | 3.2 mg | ||
| Silicon Dioxide | SILICON DIOXIDE | ETJ7Z6XBU4 | CAPSULE / RESPIRATORY (INHALATION) | NA | ||
| Ethyl Acetate | ETHYL ACETATE | 76845O8NMZ | SOLUTION / ORAL | 13 mg | ||
| D&C Red No. 7 | D&C RED NO. 7 | ECW0LZ41X8 | TABLET, COATED / ORAL | NA | ||
| D&C Red No. 7 | D&C RED NO. 7 | ECW0LZ41X8 | CAPSULE / ORAL | NA | ||
| DIMETHYLAMINOETHYL METHACRYLATE - BUTYL METHACRYLATE - METHYL METHACRYLATE COPOLYMER | DIMETHYLAMINOETHYL METHACRYLATE - BUTYL METHACRYLATE - METHYL METHACRYLATE COPOLYMER | 905HNO1SIH | CAPSULE, EXTENDED RELEASE / ORAL | 67 mg | ||
| Silicon Dioxide | SILICON DIOXIDE | ETJ7Z6XBU4 | SUSPENSION, EXTENDED RELEASE / ORAL | 70 mg | ||
| Silicon Dioxide | SILICON DIOXIDE | ETJ7Z6XBU4 | TABLET, FILM COATED / ORAL | 166 mg | ||
| Ethyl Acetate | ETHYL ACETATE | 76845O8NMZ | FILM, EXTENDED RELEASE / TRANSDERMAL | 0.05 mg | ||
| Silicon Dioxide | SILICON DIOXIDE | ETJ7Z6XBU4 | FILM, EXTENDED RELEASE / TRANSDERMAL | 49 mg | ||
| Silicon Dioxide | SILICON DIOXIDE | ETJ7Z6XBU4 | SYSTEM / TRANSDERMAL | 35 mg | ||
| D&C Red No. 7 | D&C RED NO. 7 | ECW0LZ41X8 | CAPSULE, DELAYED RELEASE / ORAL | NA | ||
| Silicon Dioxide | SILICON DIOXIDE | ETJ7Z6XBU4 | FILM, SOLUBLE / ORAL | 2 mg | ||
| Acetyltributyl Citrate | ACETYLTRIBUTYL CITRATE | 0ZBX0N59RZ | CAPSULE, COATED / ORAL | 11 mg | ||
| Silicon Dioxide | SILICON DIOXIDE | ETJ7Z6XBU4 | CAPSULE / ORAL | 300 mg | ||
| Isopropyl Alcohol | ISOPROPYL ALCOHOL | ND2M416302 | GEL / TOPICAL | 75 mg | ||
| D&C Red No. 7 | D&C RED NO. 7 | ECW0LZ41X8 | TABLET / SUBLINGUAL | 0.01 mg | ||
| D&C Red No. 7 | D&C RED NO. 7 | ECW0LZ41X8 | TABLET, EXTENDED RELEASE / ORAL | NA | ||
| DIMETHYLAMINOETHYL METHACRYLATE - BUTYL METHACRYLATE - METHYL METHACRYLATE COPOLYMER | DIMETHYLAMINOETHYL METHACRYLATE - BUTYL METHACRYLATE - METHYL METHACRYLATE COPOLYMER | 905HNO1SIH | TABLET, ORALLY DISINTEGRATING / ORAL | 222 mg | ||
| Silicon Dioxide | SILICON DIOXIDE | ETJ7Z6XBU4 | TABLET, FILM COATED, EXTENDED RELEASE / ORAL | 336 mg | ||
| Silicon Dioxide | SILICON DIOXIDE | ETJ7Z6XBU4 | CAPSULE, DELAYED RELEASE / ORAL | 40 mg | ||
| DIMETHYLAMINOETHYL METHACRYLATE - BUTYL METHACRYLATE - METHYL METHACRYLATE COPOLYMER | DIMETHYLAMINOETHYL METHACRYLATE - BUTYL METHACRYLATE - METHYL METHACRYLATE COPOLYMER | 905HNO1SIH | TABLET, FILM COATED / ORAL | 100 mg | ||
| Ethyl Acetate | ETHYL ACETATE | 76845O8NMZ | SOLUTION / TOPICAL | 31 %w/w | ||
| Silicon Dioxide | SILICON DIOXIDE | ETJ7Z6XBU4 | SUPPOSITORY / RECTAL | 14 mg | ||
| Silicon Dioxide | SILICON DIOXIDE | ETJ7Z6XBU4 | TABLET, CHEWABLE, EXTENDED RELEASE / ORAL | 2 mg | ||
| Isopropyl Alcohol | ISOPROPYL ALCOHOL | ND2M416302 | SPONGE / TOPICAL | 4 %w/w | ||
| DIMETHYLAMINOETHYL METHACRYLATE - BUTYL METHACRYLATE - METHYL METHACRYLATE COPOLYMER | DIMETHYLAMINOETHYL METHACRYLATE - BUTYL METHACRYLATE - METHYL METHACRYLATE COPOLYMER | 905HNO1SIH | TABLET, CHEWABLE / ORAL | 18 mg | ||
| Silicon Dioxide | SILICON DIOXIDE | ETJ7Z6XBU4 | TABLET, FOR SUSPENSION / ORAL | 220 mg | ||
| Silicon Dioxide | SILICON DIOXIDE | ETJ7Z6XBU4 | TABLET / ORAL | 750 mg | ||
| Silicon Dioxide | SILICON DIOXIDE | ETJ7Z6XBU4 | TABLET, CHEWABLE / ORAL | 254 mg | ||
| Silicon Dioxide | SILICON DIOXIDE | ETJ7Z6XBU4 | GRANULE, FOR SUSPENSION / ORAL | 200 mg | ||
| Ethyl Acetate | ETHYL ACETATE | 76845O8NMZ | CAPSULE, EXTENDED RELEASE / ORAL | 382.26 mg | ||
| DIMETHYLAMINOETHYL METHACRYLATE - BUTYL METHACRYLATE - METHYL METHACRYLATE COPOLYMER | DIMETHYLAMINOETHYL METHACRYLATE - BUTYL METHACRYLATE - METHYL METHACRYLATE COPOLYMER | 905HNO1SIH | PELLET / ORAL | 55 mg | ||
| Silicon Dioxide | SILICON DIOXIDE | ETJ7Z6XBU4 | PASTE / DENTAL | 34 %w/w | ||
| Acetyltributyl Citrate | ACETYLTRIBUTYL CITRATE | 0ZBX0N59RZ | CAPSULE, EXTENDED RELEASE / ORAL | 23 mg | ||
| Acetyltributyl Citrate | ACETYLTRIBUTYL CITRATE | 0ZBX0N59RZ | TABLET, DELAYED RELEASE / ORAL | 69 mg | ||
| Silicon Dioxide | SILICON DIOXIDE | ETJ7Z6XBU4 | GEL / TOPICAL | 6 mg | ||
| Silicon Dioxide | SILICON DIOXIDE | ETJ7Z6XBU4 | TAMPON / VAGINAL | NA | ||
| Silicon Dioxide | SILICON DIOXIDE | ETJ7Z6XBU4 | TABLET, DELAYED RELEASE / ORAL | 1190 mg |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| f73e80ce-e1f9-4833-97f7-695adfb68860 | 573091aa-78a0-41e0-a6f2-ac0076e9cc8f | 2013-09-19 | Warnings | f73e80ce-e1f9-4833-97f7-695adfb68860 573091aa-78a0-41e0-a6f2-ac0076e9cc8f |
Adverse event summaries are temporarily unavailable. Other product information remains available.